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Abstract Echistatin and eristostatin are structurally homolo- 
gous disintegrins which exhibit significant functional differences 
in interaction with various integrins. We hypothesized that this 
may reflect differences in the sequences of their RGD loops: 
20 32 23 35 CKRARGDDMDDYC and CRVARGDWNDDYC , re- 
spectively. Mapping of eristostatin peptides obtained by proteo- 
lyric digestion suggested that it has the same alignment of S-S 
bridges as echistatin. Synthetic echistatin D27W resembled 
eristostatin since it had increased platelet aggregation inhibitory 
activity, increased potency to block fihrinogen binding to ¢zIIb[~3, 
and decreased potency to block vitronectin binding to ¢xv[33 as 
compared to wild-type echistatin. Since eristostatin and echista- 
tin have a similar pattern of disulfide bridges, we constructed 
molecular models of eristostatin based on echistatin NMR 
coordinates. The RGD loops of eristostatin and echistatin D27W 
were wider than echistatin's due to the placement of tryptophan 
(rather than aspartic acid) immediately after the RGD sequence. 
We propose a hypothesis that the width and shape of the RGD 
loop are important ligand structural features that affect fitting of 
ligand to the binding pocket of ¢xIIb[~3 and ¢xv[~3. 
Key words: RGD loop; Integrin ¢xlIb133; Integrin ~v[33; 
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1. Introduction 
Since the early observations by Pierschbacher and Ruoslah- 
ti [1], it is well established that the arginine-glycine-aspartic 
acid (RGD) sequence plays a critical role for the recognition 
of a number of adhesive proteins by several integrins provided 
that this sequence occurs in an appropriate conformation. It is 
also established that the amino acid adjacent o the C-termi- 
nus of short RGD peptides alters its affinity to ¢xlIb[~3 integ- 
rin, with tryptophan and phenylalanine increasing its affinity 
and hydrophilic amino acids decreasing its affinity [2]. 
Disintegrins are a family of naturally occurring proteins 
derived from viper venom which contain 49 to 84 amino acids 
including an RGD or KGD sequence and 8 to 14 cysteines 
*Corresponding author. Fax: (1) (215) 707-4003 
Abbreviations: RGD, arginine~lycine-aspartic acid; HUVEC, hu- 
man umbilical vein endothelial cell; CHO, Chinese hamster ovary; 
NMR, nuclear magnetic resonance; PBST, phosphate buffered saline- 
Tween; RMS, root-mean-square 
linked by S-S bonds. Disintegrins bind with high affinity and 
inhibit the function of several integrins, including cdlb133, 
c~vl33 and a51~l. However, they show significant variation in 
their activity and selectivity [3]. NMR-derived structures for 
the disintegrins echistatin, kistrin and flavoridin reveal that 
they possess an RGD sequence at the apex of a mobile loop 
between two 13 strands of the protein, protruding 14-17A 
from the protein core [4-6]. The RGD sequence is critical 
for the expression of biological activity of disintegrins ince 
the substitution of Arg 24 in echistatin [7] and Arg a9 and Asp 51 
in kistrin [8] results in a considerable oss of disintegrin activ- 
ity. The molecules also lose their function after reduction 
[9-11] and it appears that the pattern of intramolecular S-S 
bridges affects the activity of disintegrins [12]. Scarborough et 
al. [13] suggested that amino acids adjacent o the carboxy- 
terminal end of RGD determines electivity of disintegrins. 
Disintegrins with RGDW and RGDNP sequences were quite 
selective in inhibiting native ligand binding to cdlb133 and 
c~vl33 integrin, respectively. More recently, Lu et al. [14] dem- 
onstrated that substitution of P42A and M46Q around the 
RGD domain of the neurotoxin dendroaspin alters its prefer- 
ential anti-~Ilb133 antagonism to that of the disintegrin ele- 
gantin, which appears to recognize a different ligand binding 
site in this receptor. 
In our previous tudies, we compared biological activities of 
two disintegrins, echistatin and eristostatin. These two disin- 
tegrins share 62% sequence identity and 69% sequence simi- 
larity, including eight cysteines [15] (Fig. 1). However, they 
show significant differences in their biological activities. Eri- 
stostatin is the most potent inhibitor of ADP-induced platelet 
aggregation among disintegrins, and it binds with the same 
high affÉnity to resting and activated platelets, whereas echis- 
tatin binding affinity to resting platelets is significantly lower 
than its binding affinity to ADP-activated platelets [15]. Echis- 
tatin inhibits more strongly the binding of vitronectin to im- 
mobilized c~vl33 than fibrinogen binding to immobilized 
~xlIb133. Eristostatin is a more selective inhibitor of fibrinogen 
binding to ¢xllb[33 than vitronectin binding to ¢xvl33 [16]. 
Echistatin reacts more extensively than eristostatin with HU- 
VEC and with CHO cells transfected with cxv133. Even if eri- 
stostatin binds to ~xv133 expressed on these cells, it does not 
interfere with their adhesion to vitronectin and fibronectin. In 
contrast, echistatin has a strong anti-adhesive property 
[17,18]. We hypothesized that the differences in biological ac- 
tivities of echistatin and eristostatin may reflect differences 
in the amino acid sequences of their RGD loops: 
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Eristostat in QEEPCATGPCCRRCKFKRAGKVCRVARGDWNDDYCTGKSCDCPKNPWNG 
Echistat in ECESGPCCRNCKFLKEGTICKRARGDDMDDYCNGKTCDCPRNPHKGPAT 
Echistat in D27W ECESGPCCRNCKFLKEGTICKRARGD~R4DDYCNGKTCDCPRNPHKGPAT 
Fig. l. Aminoacidsequencesofdisintegrins with RGDloop inbo ldpr in t .  Aminoacidsarerepresentedbysingle-lettercode 
2°CKRARGDDMDDYC32 and 23CRVARGDWNDDYCaS,  
respectively. To confirm this hypothesis we first established 
that eristostatin has the same pattern of intramolecular S-S 
bridges as echistatin. We then compared the interaction of 
these two disintegrins and one echistatin analogue with puri- 
fied receptors and developed molecular structures of these 
proteins. 
2. Mater ia l s  and methods  
2.1. Materials 
CHO cells transfected with ctv[33 were kindly provided by Drs. J. 
Loftus and M. Ginsberg, Scripps Research Institute, La Jolla, CA. 
Purified fibrinogen and polyclonal rabbit anti-fibrinogen (R97) were 
the gifts of Dr. Andrei Budzynski, Temple University, Philadelpha, 
PA. Anti-human vitronectin was from Gibco BRL. Alkaline phospha- 
tase-conjugated secondary antibodies and purified human vitronectin 
were obtained from Sigma. 
2.2. Preparation and characterization of disintegrins 
Eristostatin and echistatin were purified into homogeneity from the 
crude venom of Eristocophis macmahoni and Echis carinatus, respec- 
tively, using two-step C-18 reversed-phase HPLC by the method of 
Williams et al. [19]. Synthetic echistatinwt and echistatin D27W were 
provided by Dr. Victor Garsky (Merck Sharp and Dohme Research 
Laboratories, West Point, PA). The amino acid sequences for these 
four proteins are shown in Fig. 1. The concentrations of eristostatin, 
echistatin and echistatin D27W that inhibited ADP-induced platelet 
aggregation (IC~0) determined as previously described [19] were 
59+22 nM, 139+17 nM and 83+16 nM, respectively. Synthetic 
echistatin was identical in this functional assay to native echistatin. 
2.3. Determination of disulfide arrangement in er&tostatin 
This was determined as previously described for echistatin [20]. 
Eristostatin (2 mg/ml in 100 mM NH4HCO3, pH 8.0) was digested 
with TPCK-trypsin at a protein/enzyme ratio of 100:1 (w/w) for 18 h 
at 37°C. Eristostatin (1 mg/ml in 250 mM oxalic acid) was also de- 
graded in a degassed, sealed ampule for 5 h at 100°C [21]. The hydro- 
lysates were lyophilized and the peptides were isolated by reversed- 
phase HPLC using a Lichrospher RP100C18 column (24×0.4 cm, 5 
gm particle size) eluting at 1 ml/min with a mixture of 0.1% trifluor- 
acetic acid in water (solution A) and acetonotrile (solution B) isocra- 
tically (100% A) for 5 min, followed by 0-30% B for 130 min, and 30- 
70% B for 40 min. Peptides were detected at 220 nm and collected 
manually. N-terminal sequence analyses were performed with an Ap- 
plied Biosystems 470A sequencer following the manufacturer's in- 
structions. Mass spectra were recorded with a mass spectrometer 
MAT 900 equipped with liquid secondary ion ionization system and 
a fast atom bombardment gun. 
2.4. Preparation of isolated integrins (allb~3 and Ixv~3) 
Platelet membrane o~IIb133 complex was isolated from outdated 
platelets as described by Cook et al. [22]. ~v[33 was prepared from 
CHO cells transfected with human ave3 genes (VNRC3 cells), as 
described by Marcinkiewicz et al. [18]. 
2.5. Inhibitory activity of disintegrins in integrin ELISA 
Purified integrins alIb~3 and ctv133 (300 ng/well) were immobilized 
on 96-well microtiter plates overnight at 4°C in carbonate/bicarbonate 
buffer, pH 9.2. The plates were blocked with 5% (w/v) milk in PBST 
buffer. Varying concentrations of disintegrins (0-2000 pM) were 
mixed with ligand (fibrinogen or vitronectin, 1 gg) in buffer contain- 
ing 20 mM Tris-HC1, pH 7.4, 150 mM NaC1, 1 mM CaCI2, 1 mM 
MgC12, 1% (w/v) BSA, and incubated for 30 min at 37°C. After 
washing the wells with PBST, polyclonal anti-vitronectin or anti-fibri- 
nogen was added. The amount of bound ligand was detected by the 
addition of goat anti-rabbit antibody conjugated to alkaline phospha- 
tase, using nitrophenol phosphate as substrate. Testing of purified 
ctlIbl]3 or ctv133 binding to immobilized isintegrins was done as pre- 
viously described [17]. 
2.6. Computer modeling of echistat&, er&tostatin and echisD27W 
The 3-dimensional structure of synthetic echistatin has been deter- 
mined in aqueous olution by NMR [23]. A comparison of amino acid 
sequences between echistatin and eristostatin showed 62% identity and 
69% sequence similarity (Fig. 1). All eight cysteine residues are com- 
pletely conserved. In addition, we report here that the cysteine di- 
sulfide bridge pattern in eristostatin s identical to that in echistatin. 
The 3-dimensional NMR structure of echistatin reveals that the four 
disulfide bridges maintain its globular nature. Due to the high se- 
quence identity, completely conserved cysteines and identical disulfide 
pattern, the overall folding of the polypeptide backbone of eristostatin 
would be very similar to that of echistatin. The 3-dimensional struc- 
ture of eristostatin was built using the coordinates of an experimen- 
tally determined echistatin structure, using the computer program 
FRODO [24] on an ESV graphics ystem. The model was optimized 
for stereochemistry and then refined using the conjugate gradient en- 
ergy minimization method of Powell [25]. The energy-minimized struc- 
ture of eristostatin was further efined with a slow-cooling simulated 
annealing molecular dynamics procedure using X-PLOR [26]. Various 
molecular dynamics protocols used in developing the 3-dimensional 
structure of eristostatin, and in searching the conformational space for 
global minima, converged to the same 3-dimensional folding of the 
molecule. The orientation of residue side chain atoms was optimized 
using rotomer dictionary. In contrast o Pfaff et al. [27], who used 
such C~ atom distances to describe the RGD loop in a series of small 
Table 1 
Effect of variation in the disintegrin RGD loop on protein inhibitory activity with alIb[33 and txvJ]3 
Protein ICs0 (pM) C~ distances (nm) 
F~aIIb~3 V~av~3 I - - ]  
RGDX 
I I 
XARGDX 
Echistatinwt 685 + 34 218 + 38 0.58 0.91 
Eristostatin 115 + 2 1671 + 46 0.82 0.70 
Echistatin D27W 113 + 5 616 + 29 0.85 0.88 
Echistatin R22V/D27W n.d. n.d. 0.82 0.74 
Proteins were tested for inhibitory activity with immobilized integrin in the presence of native ligand in an ELISA system. Distances between Ca 
positions of various residues of the RGD loop were obtained from computer modeling. 
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Eristostatin 
1 I0 20 30 40 
 EEPCATGPCCaRCKrK   CaV GDWNDDYCTGKSCDCPaNPWNG 
TPCK-trypsin digest products: 
1 QEEPCATGPCCR 12 
14 CK 15 
22 VCR 24 
28 GDWNDDYCTGK 38 
39 SCDCPR 44 
Degradation products after incubation with 250 mM oxalic acid: 
Fragment (M+H) ÷ Ass ignment Cyste ine 
pa i r ing  
E-19 794 . 4 4PCATGP~ 
14CK15 5-14 
E-2 0 1192.3 22VCRVAR27 
41DCPR44 
10 63.5 21KVCRVAR27 
41DC42 or 4°CD41 23-(40/42) 
E-22 1175.2 6ATGPCI° or SCATGP9 
31NDDYCT3~ ( 5/10 ) -35 
E-23 934.2 2 IKVCRV 25 
41DCP 43 
835.3 21KVCR24 
41DCm43 23-42 
E- 2 5 110 4.4 19AGKVCRV25 
42CPR44 23-42 
E-29 1258.3 21KVCRVA 2~ 
42CPRNP46 
141 
1131.4 22VCRVA2~ 
42CPRNP4~ 23-42 
Fig. 2. Amino acid sequence of eristostatin and of peptides obtained by its digestion with TPCK-trypsin or degradation with 250 mM oxalic 
acid. The numbers of amino acid residues are marked on the top of eristostatin. The numbers at the left and right side of each peptide indicate 
its N- and C-terminal residues, respectively, and its localization within the eristostatin molecule. Peptides within brackets represent disulfide- 
binded polypeptides. M+H + indicates the molecular mass of the protonated molecular ion determined by mass spectrometry. In the right col- 
umn, the cysteines contained in each substructure are indicated. 
cyclic RGD peptides, we measured the distances between Ca atoms of 
selected residues in the RGD loop since they are part of the polypep- 
tide backbone and are more descriptive of the position of the loop 
itself, rather than the more flexible side chains in the loop. In general, 
the methods employed here in developing the mutant models based on 
experimentally determined structures have shown a remarkable re- 
producibility with other proteins, such as HIV protease [28], 
and have been found to be consistent with X-ray crystallographic 
results. 
3. Results and discussion 
Fig. 2 summarizes the amino acid sequences of eristostatin 
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a 
Fig. 3. Molecular structures of echistatin (a), eristostatin (b), echistatin D27W (c) and echistatin R22V/D27W (d), based on echistatin's NMR 
coordinates, built using the program FRODO, refined using conjugate gradient energy minimalization and simulated annealing molecular dy- 
namics. Residue backbones are color-coded as follows: green, hydrophobic; blue, positively charged; red, negatively charged; yellow, contain- 
ing sulfur; pink/pale blue, hydrophilic; white, tryptophan; magenta, asparagine/glutamine; cyan, glycine/proline. The side chains of the amino 
acids at the XARGDX loop are shown as ball-and-stick models. 
and its peptides obtained by its digestion with TPCK-trypsin 
or degradation with oxalic acid, and subsequently analyzed by 
mass spectrometry. Although we cannot distinguish in frag- 
ment E-22 (M+H + = 1175.2) whether C35 is linked with C5 or 
C10, the bond C5-C35 can be ruled out because C5 forms a 
bridge with C14 in fragment E-19 (M+H + = 794.4). In addi- 
tion, connection between C8-C37 should be deduced by ex- 
clusion. This structure is the same as for echistatin [20]. 
Table 1 shows that echistatin D27W had an inhibitory po- 
tency to block fibrinogen binding to immobilized ctlIb~3 that 
was higher than that of wild-type echistatin. On the other 
hand, this D27W substitution decreased the ability of echis- 
tatin to inhibit vitronectin binding to etv~3, but to an inter- 
mediate level between wild-type echistatin and eristostatin. 
Similar results were obtained when we tested the binding of 
ctIIb~3 and ¢tvl]3 to immobilized eristostatin, echistatin and 
echistatin D27W (data not shown). 
To explain the differences in biological activities among 
both disintegrins and echistatin D27W, we developed molecu- 
lar structures for each protein (Fig. 3), based on echistatin 
NMR coordinates. Echistatin is predominantly a loop struc- 
ture with four nonstandard turns and has no secondary struc- 
tural elements. The folding force is largely due to the four 
disulfide bridges between eight cysteine residues. The structure 
does not have a hydrophobic core. The three loops and the N- 
terminal part of the molecule are held together through four 
cystine bridges (Fig. 3a). The model for eristostatin (Fig. 3b) 
developed through homology modeling, refined by energy 
minimization and molecular dynamics, compares well with 
the echistatin structure. The rms deviations in C~x coordinates 
between the two proteins is 3.3 .~. Although the overall fold- 
ing in these two molecules i  very similar, the large rms devia- 
tions in Cct coordinates i due to the difference in the width of 
the RGD loop and the C-terminus of the protein. The total 
energy calculated by considering various interactions (electro- 
static, van der Waal's, etc.) for echistatin is -1112 kcal, and 
for eristostatin is -1092 kcal. In the development of this 
eristostatin structure from the experimentally determined 
structure of echistatin, various protocols of molecular dy- 
namics simulation were used, all resulting in the same global 
fold. The presence of tryptophan (W30), which is a large 
hydrophobic residue, following the RGD sequence in eristos- 
tatin makes the RGD loop significantly wider than the RGD 
loop in echistatin, which has aspartic acid (D27) following the 
RGD sequence. The rms deviations between the Cct positions 
of the sequence XARGDX in eristostatin and echistatin is 
2.1 ,~. 
The model developed for the echistatin analog D27W shows 
a similar increase in the width of the RGD loop, shown in 
Fig. 3c. In addition, the two residues Val and Trp 
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(VARGDW) in eristostatin's RGD loop clearly show hydro- 
phobic interactions between them, which are important for 
the additional stability of the RGD loop. The structure of 
the double mutant of echistatin (R22V/D27W), developed 
using the same molecular dynamics methods, demonstrated 
a shape and size of the RGD loop which is very similar to 
that of eristostatin. The rms deviations in Ca coordinates of 
the sequence VARGDW in eristostatin and echistatin R22V/ 
D27W is 0.9 A. 
Table 1 shows that eristostatin and echistatin D27W have 
the same width of the RGD loop (measured as the distance 
between Ca of RGDX) which is greater than the width of the 
echistatin loop. This width of the loop seems to correlate with 
the binding affinity to t~IIb~3 since both eristostatin and 
echistatin D27W have similar inhibitory effect on the binding 
of ctIIb~3 to fibrinogen and similar platelet aggregation i hib- 
itory activity. The width of eristostatin's RGD loop compared 
with that of echistatin depends on the placement of trypto- 
phan (rather than aspartic acid) immediately after the RGD 
sequence. However, the ability of echistatin D27W to inhibit 
binding of vitronectin to av[33 was intermediate between that 
of echistatin or eristostatin. Interestingly, the shape of the 
RGD loop (measured as the distance between Cc~ of 
XARGDX) is very similar in echistatin and echistatin 
D27W. The shape of the loop was ultimately determined by 
the two amino acid residues N-terminal to the RGD se- 
quence: valine in eristostatin and arginine in both echistatinwt 
and echistatin D27W. This was also confirmed by creating a 
computer model of a second echistatin variant. Replacing R22 
in echistatin with valine and D27 with tryptophan gave an 
echistatin molecule which could be superimposed on eristos- 
tatin (Fig. 3d and Table 1). Since echistatin D27W is less 
selective to ctv133 than wild-type echistatin, but is still much 
more selective than eristostatin (Table 1), it is possible that the 
second substitution (R22V) in echistatin will bestow compar- 
able selectivity as eristostatin. On the basis of our studies, we 
propose a hypothesis that while the width of the RGD loop is 
an important ligand structural feature creating an optimal fit 
to the binding pocket of ctlIbl]3, the shape of the loop, influ- 
enced by the amino acids nearer the disulfide bridge itself, is a 
major determinant in whether an RGD-containing ligand will 
bind to the vitronectin receptor. This hypothesis has to be 
confirmed experimentally b creating an echistatin double mu- 
tant, R22V/D27W, and assessing its affinity to ctv133 in com- 
parison to both wild-type chistatin and eristostatin. Our data 
confirm and extend the observations of Pfaff et al. [27], who 
have shown that larger distances between C13 atoms of argi- 
nine and aspartic acid in cyclic RGD peptides imparts a se- 
lectivity for ctlIb133 versus either ctv133 or tx5131 binding. 
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